Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Income
$35.4M
Filings
839
Unique Clients
16
Active Period
2010–2026
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
2018 · fourth_quarter · Client: DAIICHI SANKYO INC
HR 2025, Abuse-Deterrent Opioids Plan for Tomorrow Act; and FDA regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: HR 2025
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
2018 · fourth_quarter · Client: PFENEX INC
General health care coverage and reimbursement for prescription drugs; regulatory issues related to biodefense vaccine development and procurement; H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; and the Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 6378
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
2018 · fourth_quarter · Client: BAVARIAN NORDIC INC
General health care coverage and reimbursement for prescription drugs; Regulatory issues related to biodefense vaccine development and procurement; H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act; and the Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 6378
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
2018 · third_quarter · Client: PAXVAX
H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; Health and Human Services Appropriations, FDA regulatory issues and issues related to Priority Review Voucher programs.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 6378
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
2018 · third_quarter · Client: DAIICHI SANKYO INC
HR 2025, Abuse-Deterrent Opioids Plan for Tomorrow Act; and FDA regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: HR 2025
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
2018 · third_quarter · Client: PFENEX INC
General health care coverage and reimbursement for prescription drugs; regulatory issues related to biodefense vaccine development and procurement; H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; and the Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 6378
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
2018 · third_quarter · Client: BAVARIAN NORDIC INC
General health care coverage and reimbursement for prescription drugs; Regulatory issues related to biodefense vaccine development and procurement; H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act; and the Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 6378
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
2018 · second_quarter · Client: PAXVAX
H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; Health and Human Services Appropriations, FDA regulatory issues and issues related to Priority Review Voucher programs.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 6378
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
2018 · second_quarter · Client: DAIICHI SANKYO INC
HR 2025, Abuse-Deterrent Opioids Plan for Tomorrow Act; and FDA regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: HR 2025
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
2018 · second_quarter · Client: PFENEX INC
General health care coverage and reimbursement for prescription drugs; regulatory issues related to biodefense vaccine development and procurement; H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; and the Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 6378
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
2018 · second_quarter · Client: BAVARIAN NORDIC INC
General health care coverage and reimbursement for prescription drugs; Regulatory issues related to biodefense vaccine development and procurement; H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act; and the Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 6378
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
2018 · first_quarter · Client: DAIICHI SANKYO INC
HR 2025, Abuse-Deterrent Opioids Plan for Tomorrow Act; and FDA regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: HR 2025
Environmental Justice and Civil Rights Restoration and Enforcement Act
2018 · first_quarter · Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
General health care coverage and reimbursement for prescription drugs; reforms to H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 3590
Environmental Justice and Civil Rights Restoration and Enforcement Act
2018 · first_quarter · Client: GLAXOSMITHKLINE
General health care coverage and reimbursement for prescription drugs; reforms to H.R. 3590, the Patient Protection and Affordable Care Act; regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; and the Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3590
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
2017 · fourth_quarter · Client: DAIICHI SANKYO INC
HR 2025, Abuse-Deterrent Opioids Plan for Tomorrow Act; and FDA regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: HR 2025
Environmental Justice and Civil Rights Restoration and Enforcement Act
2017 · fourth_quarter · Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
General health care coverage and reimbursement for prescription drugs; reforms to H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 3590
Environmental Justice and Civil Rights Restoration and Enforcement Act
2017 · fourth_quarter · Client: GLAXOSMITHKLINE
General health care coverage and reimbursement for prescription drugs; reforms to H.R. 3590, the Patient Protection and Affordable Care Act; regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; and the Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3590
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
2017 · third_quarter · Client: DAIICHI SANKYO INC
HR 2025, Abuse-Deterrent Opioids Plan for Tomorrow Act; and FDA regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: HR 2025
Environmental Justice and Civil Rights Restoration and Enforcement Act
2017 · third_quarter · Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
General health care coverage and reimbursement for prescription drugs; implementation of and reforms to H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 3590
Environmental Justice and Civil Rights Restoration and Enforcement Act
2017 · third_quarter · Client: GLAXOSMITHKLINE
General health care coverage and reimbursement for prescription drugs; implementation of and reforms to H.R. 3590, the Patient Protection and Affordable Care Act; regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; and the Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3590
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
2017 · second_quarter · Client: DAIICHI SANKYO INC
Prescription Drug User Fee Act Re-authorization; HR 2025, Abuse-Deterrent Opioids Plan for Tomorrow Act.
Client expense: — · Firm income: $15,000
Matched citations: HR 2025
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
2017 · second_quarter · Client: DAIICHI SANKYO INC
Prescription Drug User Fee Act Re-authorization, H.R. 2025, the Abuse-Deterrent Opioids Plan for Tomorrow Act.
Client expense: — · Firm income: —
Matched citations: H.R. 2025
Environmental Justice and Civil Rights Restoration and Enforcement Act
2017 · second_quarter · Client: NOVARTIS
General health care coverage and reimbursement for prescription drugs; implementation of and reforms to H.R. 3590, the Patient Protection and Affordable Care Act; issues related to the 21st Century Cures Act; and the Food and Drug Administration legislative and regulatory issues, including the Prescription Drug User Fee Act Re-authorization.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 3590
Medical Countermeasure Innovation Act of 2016
2017 · second_quarter · Client: PFENEX INC
General health care coverage and reimbursement for prescription drugs; S. 2055, the Medical Countermeasure Innovation Act; regulatory issues related to biodefense vaccine development and procurement; and the Food and Drug Administration legislative and regulatory issues, including the Prescription Drug User Fee Act Re-authorization.
Client expense: — · Firm income: $45,000
Matched citations: S. 2055
Environmental Justice and Civil Rights Restoration and Enforcement Act
2017 · second_quarter · Client: ALERE INC.
Issues relate to appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies; implementation of and reforms to H.R. 3590, the Patient Protection and Affordable Care Act related to diagnostics; issues related to diagnostics in the 21st Century Cures Act; and the Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 3590
Source: Senate LDA